image

ISSN: 1935-1232 (P)

ISSN: 1941-2010 (E)

image
image

Citations Report

Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

  2022 2021 2020 2019 2018

Total published articles

105 141 28 8 28

Conference proceedings

0 0 0 0 0

Citations received as per Google Scholar, other indexing platforms and portals

543 553 590 563 587
Journal total citations count 6601
Journal impact factor 6.49
Journal 5 years impact factor 12.17
Journal cite score 11.19
Journal h-index 41
Journal h-index since 2019 26
Baird, John D., and George A. Maylin. "Adverse side effects in horses following the administration of fluphenazine decanoate." In Proceedings of the AAEP’s 57th Annual Convention, Nov, pp. 18-22. 2011.
Liu, Liang, Yin Luo, Guofu Zhang, Chunhui Jin, Zhenhe Zhou, Zaohuo Cheng, and Guozhen Yuan. "Correlation of DRD2 mRNA expression levels with deficit syndrome severity in chronic schizophrenia patients receiving clozapine treatment." Oncotarget 8, no. 49 (2017): 86515.
Miller, Brian J., and David R. Goldsmith. "Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology." Biomarkers in Neuropsychiatry 1 (2019): 100006.
Gatch, Michael B., Sean B. Dolan, and Michael J. Forster. "Locomotor activity and discriminative stimulus effects of five novel synthetic cathinone analogs in mice and rats." Drug and alcohol dependence 199 (2019): 50-58.
Scott, Daniel, and Carol A. Tamminga. "Effects of genetic and environmental risk for schizophrenia on hippocampal activity and psychosis-like behavior in mice." Behavioural brain research 339 (2018): 114-123.
Okbay, Aysu, Bart ML Baselmans, Jan-Emmanuel De Neve, Patrick Ansel Turley, Michel G. Nivard, Mark A. Fontana, Fleur SW Meddens et al. "Genetic associations with subjective well-being also implicate depression and neuroticism." Nature Genetics (2016).
Ray, Azizi, Neha Milind Chitre, Cedrick Maceo Daphney, Bruce E. Blough, Clinton E. Canal, and Kevin Sean Murnane. "Effects of the second-generation" bath salt" cathinone alpha-pyrrolidinopropiophenone (?-PPP) on behavior and monoamine neurochemistry in male mice." Psychopharmacology 236, no. 3 (2019): 1107-1117.
Buhusi, Mona, Kaitlin Olsen, and Catalin V. Buhusi. "Increased temporal discounting after chronic stress in CHL1-deficient mice is reversed by 5-HT2C agonist Ro 60-0175." Neuroscience 357 (2017): 110-118.
Pratt, Judith A., Brian Morris, and Neil Dawson. "Deconstructing schizophrenia: Advances in preclinical models for biomarker identification." Biomarkers in Psychiatry (2018): 295-323.
Smid, Marcela C., Torri D. Metz, and Adam J. Gordon. "Stimulant use in pregnancy–An under-recognized epidemic among pregnant women." Clinical obstetrics and gynecology 62, no. 1 (2019): 168.
Nakatani, Yoshio, Yosuke Shimaki, Debajyoti Dutta, Stephen P. Muench, Keith Ireton, Gregory M. Cook, and Lars JC Jeuken. "Unprecedented properties of phenothiazines unraveled by a NDH-2 bioelectrochemical assay platform." Journal of the American Chemical Society 142, no. 3 (2019): 1311-1320.
Fernando Muñoz, Luis, and Luis Eduardo Jaramillo. "DSM-5:¿ Cambios significativos?." Revista de la Asociación Española de Neuropsiquiatría 35, no. 125 (2015): 111-121.
Schifano, Fabrizio, Flavia Napoletano, Stephania Chiappini, Amira Guirguis, J. M. Corkery, Stefania Bonaccorso, Angelo Ricciardi, Norbert Scherbaum, and A. Vento. "New/emerging psychoactive substances and associated psychopathological consequences." Psychological medicine 51, no. 1 (2021): 30-42.
Koola, Maju Mathew, Jeffrey K. Raines, Robert G. Hamilton, and Robert P. McMahon. "Can anti-inflammatory medications improve symptoms and reduce mortality in schizophrenia?." Current psychiatry 15, no. 5 (2016): 52.
Hassan, Zurina, Oliver G. Bosch, Darshan Singh, Suresh Narayanan, B. Vicknasingam Kasinather, Erich Seifritz, Johannes Kornhuber, Boris B. Quednow, and Christian P. Müller. "Novel psychoactive substances—recent progress on neuropharmacological mechanisms of action for selected drugs." Frontiers in psychiatry 8 (2017): 152.
Kessas, Mona, Meaghan Creed, and José N. Nobrega. "An examination of synaptic proteins following chronic haloperidol in a rat model of tardive dyskinesia." Psychology & Neuroscience 3, no. 2 (2010): 229-237.
Colon-Perez, Luis M., Kelvin Tran, Khalil Thompson, Michael C. Pace, Kenneth Blum, Bruce A. Goldberger, Mark S. Gold, Adriaan W. Bruijnzeel, Barry Setlow, and Marcelo Febo. "The psychoactive designer drug and bath salt constituent MDPV causes widespread disruption of brain functional connectivity." Neuropsychopharmacology 41, no. 9 (2016): 2352-2365.
Karila, Laurent, Joel Billieux, Amine Benyamina, Christophe Lançon, and Olivier Cottencin. "The effects and risks associated to mephedrone and methylone in humans: a review of the preliminary evidences." Brain research bulletin 126 (2016): 61-67.
Ellefsen, Kayla N., Marta Concheiro, and Marilyn A. Huestis. "Synthetic cathinone pharmacokinetics, analytical methods, and toxicological findings from human performance and postmortem cases." Drug metabolism reviews 48, no. 2 (2016): 237-265.
Kessas, Mona, Meaghan Creed, and José N. Nobrega. "An examination of synaptic proteins following chronic haloperidol in a rat model of tardive dyskinesia." Psychology & Neuroscience 3, no. 2 (2010): 229-237.